Nothing Special   »   [go: up one dir, main page]

EA202091315A3 - Антитела человека, связывающиеся с g-белком rsv - Google Patents

Антитела человека, связывающиеся с g-белком rsv

Info

Publication number
EA202091315A3
EA202091315A3 EA202091315A EA202091315A EA202091315A3 EA 202091315 A3 EA202091315 A3 EA 202091315A3 EA 202091315 A EA202091315 A EA 202091315A EA 202091315 A EA202091315 A EA 202091315A EA 202091315 A3 EA202091315 A3 EA 202091315A3
Authority
EA
Eurasian Patent Office
Prior art keywords
human antibodies
antibodies binding
rsv
protein rsv
protein
Prior art date
Application number
EA202091315A
Other languages
English (en)
Other versions
EA202091315A2 (ru
Inventor
Джехангир Вадиа
Роберт Энтони Уилльямсон
Йоханнес Петрус Мария Лангедейк
Габриель Паскуал
Анжелик Ван 'т Воут
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA202091315A2 publication Critical patent/EA202091315A2/ru
Publication of EA202091315A3 publication Critical patent/EA202091315A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)

Abstract

Настоящее изобретение предлагает выделенные антитела и их антигенсвязывающие фрагменты, которые специфично связываются с G-белком RSV и которые способны нейтрализовать RSV.
EA202091315A 2013-08-05 2014-04-14 Антитела человека, связывающиеся с g-белком rsv EA202091315A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13179242 2013-08-05

Publications (2)

Publication Number Publication Date
EA202091315A2 EA202091315A2 (ru) 2021-01-29
EA202091315A3 true EA202091315A3 (ru) 2021-06-30

Family

ID=48914152

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591974A EA035846B1 (ru) 2013-04-15 2014-04-14 Антитела человека, связывающиеся с g-белком rsv
EA202091315A EA202091315A3 (ru) 2013-08-05 2014-04-14 Антитела человека, связывающиеся с g-белком rsv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201591974A EA035846B1 (ru) 2013-04-15 2014-04-14 Антитела человека, связывающиеся с g-белком rsv

Country Status (10)

Country Link
US (1) US10035842B2 (ru)
EP (2) EP3567052A1 (ru)
JP (1) JP6416212B2 (ru)
KR (1) KR102201555B1 (ru)
CN (1) CN105164155B (ru)
AU (1) AU2014255865B2 (ru)
CA (1) CA2908921C (ru)
EA (2) EA035846B1 (ru)
TW (1) TWI637964B (ru)
WO (1) WO2014170258A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416212B2 (ja) 2013-04-15 2018-10-31 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖｇタンパク質に結合するヒト抗体
EA035861B1 (ru) 2013-04-15 2020-08-21 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
SI2988780T1 (sl) 2013-04-25 2019-05-31 Janssen Vaccines & Prevention B.V. Stabilizirani topni prefuzijski RSV F polipeptidi
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
KR20170023124A (ko) 2014-06-26 2017-03-02 얀센 백신스 앤드 프리벤션 비.브이. 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V Vaccine against rsv
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CA3018941A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CN109311968A (zh) * 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
AU2017272504A1 (en) 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
CA3107037A1 (en) * 2018-08-08 2020-02-13 Trellis Bioscience, Llc Improved rsv passive and active vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1533380B1 (en) 1999-04-15 2009-11-04 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
KR20090127341A (ko) * 2007-03-06 2009-12-10 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
WO2009055711A2 (en) 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies
MX2011000668A (es) * 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Antigenos quimericos polipeptidicos del virus sincitial respiratorio.
WO2010075491A2 (en) 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
TWI577238B (zh) 2012-04-25 2017-04-01 群康科技(深圳)有限公司 有機發光二極體及包含其之顯示裝置
JP6416212B2 (ja) 2013-04-15 2018-10-31 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖｇタンパク質に結合するヒト抗体
EA035861B1 (ru) 2013-04-15 2020-08-21 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv

Also Published As

Publication number Publication date
KR102201555B1 (ko) 2021-01-12
US20160145322A1 (en) 2016-05-26
US10035842B2 (en) 2018-07-31
KR20150143545A (ko) 2015-12-23
JP2016522804A (ja) 2016-08-04
EP3567052A1 (en) 2019-11-13
EA035846B1 (ru) 2020-08-20
AU2014255865B2 (en) 2019-07-18
EP2986638A1 (en) 2016-02-24
EA201591974A1 (ru) 2016-04-29
CA2908921A1 (en) 2014-10-23
WO2014170258A1 (en) 2014-10-23
JP6416212B2 (ja) 2018-10-31
EA202091315A2 (ru) 2021-01-29
CA2908921C (en) 2022-07-19
AU2014255865A1 (en) 2015-10-29
CN105164155B (zh) 2020-01-03
TWI637964B (zh) 2018-10-11
TW201534619A (zh) 2015-09-16
CN105164155A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EP3461261A4 (en) CD3 BINDING PROTEINS WITH UNIVERSAL VARIABLE FRAGMENT
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201892417A1 (ru) Антитела, распознающие тау
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201291065A1 (ru) Антитела против vla-4